Ltd is proud to become one of the 27 companies to sign licensing
agreement with the Medicines Patent Pool (MPP) to manufacture the
generic version of the oral COVID-19 antiviral medication Molnupiravir
for supply in 105 low- and-middle-income countries (LMICs).
Premia Biotech Ltd
Mobile / WhatsApp : +44 7887 477007
Email : firstname.lastname@example.org
#covid #molnupiravir #genericdrugs #antiviral #pharmaceuticalsales #premiabiotech
A great company to deal with, extremely reliable with a good range of products. Excellent product knowledge, great communication & customer service, fair prices and fast delivery.